SCHEMBL3138286

SCHEMBL3138286

O=C(O)CNC(=O)c1cc(Br)c(O)c(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.53
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
HIF1A Q16665 2/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
SLC22A8 Q8TCC7 1/20 0.49
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
MAPK1 P28482 2/20 0.44
PTPRC P08575 2/20 0.43
CTSL P07711 1/20 0.43
PTPN13 Q12923 1/20 0.43
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GFER P55789 1/20 0.42
KMT2A Q03164 1/20 0.42
EGLN2 Q96KS0 1/20 0.42
FTO Q9C0B1 1/20 0.42
EGLN3 Q9H6Z9 1/20 0.42
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30888690 0.93 TTR (0.47) TTRKDM4EMAPTHIF1ASLC22A6
SCHEMBL16144996 0.81 KDM4E (0.59) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL3259703 0.81 KDM4E (0.61) TTRKDM4EMAPTMAPK1MEN1
SCHEMBL3915611 0.80 KDM4E (0.40) TTRKDM4EMAPTHIF1ASLC22A6
SCHEMBL9580760 0.79 MAPT (0.52) TTRKDM4EMAPTHIF1ASLC22A6
SCHEMBL11486358 0.78 KDM4E (0.49) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL9705957 0.78 NTRK2 (0.49) TTRKDM4EMAPTCA1CA2
SCHEMBL6337602 0.77 CA1 (0.55) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL3243859 0.76 ALDH1A1 (0.63) TTRKDM4EMAPTHIF1ACA1
SCHEMBL13996817 0.74 KDM4E (0.49) KDM4EMAPTHIF1ASLC22A6SLC22A8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004271-A1 HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR KARO BIO AB (SE) 2010-01-07 US disclosed
US-20090318514-A1 Novel Pharmaceutical Compositions KARO BIO AB (SE) 2009-12-24 US disclosed
US-20090233979-A1 Indole Derivatives and Their Use as Thyroid Receptor Ligands KARO BIO AB (SE) 2009-09-17 US disclosed
EP-2035377-A1 INDOLE DERIVATIVES AND THEIR USE AS THYROID RECEPTOR LIGANDS KARO BIO AB (SE) 2009-03-18 EP disclosed
EP-2024336-A1 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2009-02-18 EP disclosed
EP-1899309-A1 HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR KARO BIO AB (SE) 2008-03-19 EP disclosed
US-20080004251-A1 Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor KARO BIO AB (SE) 2008-01-03 US disclosed
WO-2007134864-A1 INDOLE DERIVATIVES AND THEIR USE AS THYROID RECEPTOR LIGANDS KARO BIO AB (SE) 2007-11-29 WO disclosed
WO-2007128492-A1 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2007-11-15 WO disclosed
WO-2007003419-A1 HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR KARO BIO AB (SE) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233979-A1 Indole Derivatives and Their Use as Thyroid Receptor Ligands TSHR, TRHR, THRA TTR 1669/4885KDM4E 1169/4885MAPT 3535/4885
US-20100004271-A1 HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR TSHR, GHSR, TRHR TTR 477/4885KDM4E 1562/4885MAPT 1760/4885
US-20080004251-A1 Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor TSHR, TRHR, THRA TTR 761/4885KDM4E 2542/4885MAPT 4134/4885
US-20090318514-A1 Novel Pharmaceutical Compositions TSHR, TRHR, THRA TTR 893/4885KDM4E 1775/4885MAPT 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.